Ex vivo-model design and evaluation of the sensitivity of blast cells to chemotherapy as a way to personalize the treatment of acute myeloid leukemia

Despite continuous attempts to improve therapy, the outcomes of acute myeloid leukemia remain almost unchanged over last decades. Drugs made with a more complete understanding of the biology of acute myeloid leukemia do not equal the hopes for better prognosis. The best results are achieved only wit...

Full description

Saved in:
Bibliographic Details
Main Authors: A. S. Polyakov, Ya. A. Noskov, Yu. V. Nikitin, V. V. Tyrenko, S. N. Kolubaeva, A. N. Bogdanov, V. N. Semelev, O. R. Petrova, S. V. Bondarchuk, D. K. Zhogolev, A. D. Zolotarev, A. V. Kovalev, Yu. E. Puchkova
Format: Article
Language:Russian
Published: ABV-press 2019-07-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/349
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849409245117677568
author A. S. Polyakov
Ya. A. Noskov
Yu. V. Nikitin
V. V. Tyrenko
S. N. Kolubaeva
A. N. Bogdanov
V. N. Semelev
O. R. Petrova
S. V. Bondarchuk
D. K. Zhogolev
A. D. Zolotarev
A. V. Kovalev
Yu. E. Puchkova
author_facet A. S. Polyakov
Ya. A. Noskov
Yu. V. Nikitin
V. V. Tyrenko
S. N. Kolubaeva
A. N. Bogdanov
V. N. Semelev
O. R. Petrova
S. V. Bondarchuk
D. K. Zhogolev
A. D. Zolotarev
A. V. Kovalev
Yu. E. Puchkova
author_sort A. S. Polyakov
collection DOAJ
description Despite continuous attempts to improve therapy, the outcomes of acute myeloid leukemia remain almost unchanged over last decades. Drugs made with a more complete understanding of the biology of acute myeloid leukemia do not equal the hopes for better prognosis. The best results are achieved only with high-dose chemotherapy, which is only possible for a limited number of patients. High phenotypic and genotypic heterogeneity of acute myeloid leukemia defines the relevance to develop personalized approaches to therapy, including those based on determination of individual drug sensitivity of blast cells.This article presents the results of developing an ex-vivo model of acute myeloid leukemia, as well as testing of two in vitro sensitivity assessment methods: evaluation of the genotoxicity of drugs in the micronucleus test and vitality and sensitivity to chemotherapy in sorted blast cells. Prospects of individualized therapy of acute myeloid leukemia were determined based on introduction into clinical practice and continuing the research.
format Article
id doaj-art-e8d76bc63efc4d4898fad401b59758c0
institution Kabale University
issn 1818-8346
2413-4023
language Russian
publishDate 2019-07-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj-art-e8d76bc63efc4d4898fad401b59758c02025-08-20T03:35:33ZrusABV-pressОнкогематология1818-83462413-40232019-07-01142596910.17650/1818-8346-2019-14-2-59-69314Ex vivo-model design and evaluation of the sensitivity of blast cells to chemotherapy as a way to personalize the treatment of acute myeloid leukemiaA. S. Polyakov0Ya. A. Noskov1Yu. V. Nikitin2V. V. Tyrenko3S. N. Kolubaeva4A. N. Bogdanov5V. N. Semelev6O. R. Petrova7S. V. Bondarchuk8D. K. Zhogolev9A. D. Zolotarev10A. V. Kovalev11Yu. E. Puchkova12Military Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaMilitary Medical Academy named after S.M. Kirov, Ministry of Defense of the RussiaDespite continuous attempts to improve therapy, the outcomes of acute myeloid leukemia remain almost unchanged over last decades. Drugs made with a more complete understanding of the biology of acute myeloid leukemia do not equal the hopes for better prognosis. The best results are achieved only with high-dose chemotherapy, which is only possible for a limited number of patients. High phenotypic and genotypic heterogeneity of acute myeloid leukemia defines the relevance to develop personalized approaches to therapy, including those based on determination of individual drug sensitivity of blast cells.This article presents the results of developing an ex-vivo model of acute myeloid leukemia, as well as testing of two in vitro sensitivity assessment methods: evaluation of the genotoxicity of drugs in the micronucleus test and vitality and sensitivity to chemotherapy in sorted blast cells. Prospects of individualized therapy of acute myeloid leukemia were determined based on introduction into clinical practice and continuing the research.https://oncohematology.abvpress.ru/ongm/article/view/349acute myeloid leukemiasecondary acute myeloid leukemiaex vivo modeldrug sensitivity testinggenotoxicitymicronucleus testfluorescence activated cell sortingindividualization of drug therapy
spellingShingle A. S. Polyakov
Ya. A. Noskov
Yu. V. Nikitin
V. V. Tyrenko
S. N. Kolubaeva
A. N. Bogdanov
V. N. Semelev
O. R. Petrova
S. V. Bondarchuk
D. K. Zhogolev
A. D. Zolotarev
A. V. Kovalev
Yu. E. Puchkova
Ex vivo-model design and evaluation of the sensitivity of blast cells to chemotherapy as a way to personalize the treatment of acute myeloid leukemia
Онкогематология
acute myeloid leukemia
secondary acute myeloid leukemia
ex vivo model
drug sensitivity testing
genotoxicity
micronucleus test
fluorescence activated cell sorting
individualization of drug therapy
title Ex vivo-model design and evaluation of the sensitivity of blast cells to chemotherapy as a way to personalize the treatment of acute myeloid leukemia
title_full Ex vivo-model design and evaluation of the sensitivity of blast cells to chemotherapy as a way to personalize the treatment of acute myeloid leukemia
title_fullStr Ex vivo-model design and evaluation of the sensitivity of blast cells to chemotherapy as a way to personalize the treatment of acute myeloid leukemia
title_full_unstemmed Ex vivo-model design and evaluation of the sensitivity of blast cells to chemotherapy as a way to personalize the treatment of acute myeloid leukemia
title_short Ex vivo-model design and evaluation of the sensitivity of blast cells to chemotherapy as a way to personalize the treatment of acute myeloid leukemia
title_sort ex vivo model design and evaluation of the sensitivity of blast cells to chemotherapy as a way to personalize the treatment of acute myeloid leukemia
topic acute myeloid leukemia
secondary acute myeloid leukemia
ex vivo model
drug sensitivity testing
genotoxicity
micronucleus test
fluorescence activated cell sorting
individualization of drug therapy
url https://oncohematology.abvpress.ru/ongm/article/view/349
work_keys_str_mv AT aspolyakov exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT yaanoskov exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT yuvnikitin exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT vvtyrenko exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT snkolubaeva exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT anbogdanov exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT vnsemelev exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT orpetrova exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT svbondarchuk exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT dkzhogolev exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT adzolotarev exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT avkovalev exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia
AT yuepuchkova exvivomodeldesignandevaluationofthesensitivityofblastcellstochemotherapyasawaytopersonalizethetreatmentofacutemyeloidleukemia